A detailed history of Affinity Asset Advisors, LLC transactions in Cullinan Oncology, Inc. stock. As of the latest transaction made, Affinity Asset Advisors, LLC holds 263,817 shares of CGEM stock, worth $3.55 Million. This represents 0.76% of its overall portfolio holdings.

Number of Shares
263,817
Previous 263,817 -0.0%
Holding current value
$3.55 Million
Previous $4.6 Million 4.0%
% of portfolio
0.76%
Previous 0.63%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$15.63 - $29.35 $81,729 - $153,471
5,229 Added 2.02%
263,817 $4.6 Million
Q1 2024

May 14, 2024

SELL
$10.17 - $19.02 $421,160 - $787,656
-41,412 Reduced 13.8%
258,588 $4.41 Million
Q4 2023

Feb 13, 2024

BUY
$7.89 - $10.23 $2.37 Million - $3.07 Million
300,000 New
300,000 $3.06 Million
Q3 2021

Nov 12, 2021

SELL
$22.56 - $29.68 $1.02 Million - $1.34 Million
-45,000 Closed
0 $0
Q2 2021

Aug 13, 2021

BUY
$24.96 - $41.25 $1.12 Million - $1.86 Million
45,000 New
45,000 $1.16 Million

Others Institutions Holding CGEM

About Cullinan Oncology, Inc.


  • Ticker CGEM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,612,200
  • Market Cap $613M
  • Description
  • Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...
More about CGEM
Track This Portfolio

Track Affinity Asset Advisors, LLC Portfolio

Follow Affinity Asset Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Affinity Asset Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Affinity Asset Advisors, LLC with notifications on news.